Data on prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer: Posthoc data analysis from the phase 3 randomize d, open-lab el study comparing trab ecte din and PLD versus PLD alone in patients with recurrent ovarian cancer

被引：1

作者：

Monk, Bradley J. ^{[1
]}

Herzog, Thomas J. ^{[2
]}

Wang, George ^{[3
]}

Triantos, Spyros ^{[3
]}

Maul, Scott ^{[4
]}

Knoblauch, Roland ^{[3
]}

McGowan, Tracy ^{[5
]}

Shalaby, Waleed S. W. ^{[5
]}

Coleman, Robert L. ^{[6
]}

机构：

[1] Creighton Univ, Univ Arizona, US Oncol Network, Arizona Oncol, Phoenix, AZ 85012 USA

[2] Univ Cincinnati, Canc Ctr, Cincinnati, OH USA

[3] Janssen Res & Dev, Spring House, PA USA

[4] Janssen Res & Dev, Los Angeles, CA USA

[5] Janssen Sci Affairs LLC, Horsham, PA USA

[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

DATA IN BRIEF | 2020年 / 30卷

关键词：

Overall survival; Pegylated liposomal doxorubicin; Trabectedin; Recurrent ovarian cancer; Response rate;

D O I：

10.1016/j.dib.2020.105465

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

The data presented herein are supplementary to our published primary article "A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer"[1]. The exploratory analysis evaluated the impact of prior pegylated liposomal doxorubicin (PLD) therapy in patients who participated in a randomized, open-label study comparing combination therapy of trabectedin and PLD vs PLD alone in third-line recurrent ovarian cancer (ROC). These exploratory analyses showed that prior treatment with PLD in ROC does not impact the response and survival rates nor does it increase toxicities or negatively influence survival and response rates in both treatment groups. (C) 2020 The Author(s). Published by Elsevier Inc.

引用

页数：7

共 50 条

[1] Phase II study comparing volociximab (an antiangiogenic antibody) and pegylated liposomal doxorubicin (PLD) with PLD alone in recurrent ovarian or primary peritoneal cancer
Vergote, I. B.
Colombo, N.
Kutarska, E.
Del Campo, J.
Pippitt, C.
Casado, A.
Lengyel, E.
Gilder, K.
Ho, S.
Schilder, R. J.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[2] Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: Overall survival analysis
Monk, Bradley J.
Herzog, Thomas J.
Kaye, Stanley B.
Krasner, Carolyn N.
Vermorken, Jan B.
Muggia, Franco M.
Pujade-Lauraine, Eric
Park, Youn C.
Parekh, Trilok V.
Poveda, Andres M.
EUROPEAN JOURNAL OF CANCER, 2012, 48 (15) : 2361 - 2368
[3] A RANDOMIZED PHASE III STUDY OF TRABECTEDIN WITH PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) VERSUS PLD IN RELAPSED, RECURRENT OVARIAN CANCER (OC)
Monk, B. J.
Herzog, T.
Kaye, S.
Krasner, C. N.
Vermorken, J.
Muggia, F.
Pujade-Lourraine, E.
Renshaw, F. G.
Lebedinsky, C.
Poveda, A.
ANNALS OF ONCOLOGY, 2008, 19 : 2 - 2
[4] Final survival results of the randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer
Monk, B. J.
Herzog, T. J.
Kaye, S. B.
Krasner, C. N.
Vermorken, J. B.
Muggia, F.
Pujade-Lourraine, E.
Zintl, P.
Parekh, T. V.
Poveda, A.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[5] Impact of prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer (ROC): Sub-group analysis from a randomized, open-label study comparing trabectedin (T) and PLD versus PLD alone in ROC (ET743-OVC-3006)
Monk, B. J.
Herzog, T. J.
Triantos, S.
Maul, S.
Wang, G.
Pontes Valero, M. J.
McGowan, T.
Shalaby, W. S.
Coleman, R. L.
ANNALS OF ONCOLOGY, 2019, 30
[6] Subanalysis of a randomized phase III study comparing trabectedin and PLD vs PLD alone in patients with recurrent ovarian cancer (ROC)
Monk, B. J.
Herzog, T.
McGowan, T.
De Rivas Otero, B.
Gomez, J.
Tanovic, A.
Coleman, R. L.
ANNALS OF ONCOLOGY, 2020, 31 : S625 - S625
[7] A randomized phase III study of gemcitabine (GEM) versus pegylated liposomal doxorubicin (PLD) in progressive/recurrent ovarian cancer (OC)
Ferrandina, G.
Lorusso, D.
Pignata, S.
Breda, E.
Savarese, A.
Nardi, M.
Scaltriti, L.
Ludovisi, M.
Scambia, G.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[8] Correlation of CA-125 and RECIST evaluation in recurrent ovarian cancer (ROC): Results from a randomized phase III study of trabectedin (T) with pegylated liposomal doxorubicin (PLD) versus PLD alone
Herzog, T. J.
Vermorken, J. B.
Pujade-Lauraine, E.
Li, J.
Bayever, E.
Gomez, J.
Yovine, A.
Monk, B. J.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[9] Phase II study of pegylated liposomal doxorubicin (PLD) and oxaliplatin (L-OHP) in recurrent ovarian cancer (ROC)
Recchia, Francesco
Saggio, Gaetano
Amiconi, Giovanna
Di Blasio, Anna
Cesta, Alisia
Candeloro, Giampiero
Carta, Gaspare
Rea, Silvio
ANNALS OF ONCOLOGY, 2006, 17 : 171 - 171
[10] Pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) given alone and with bevacizumab (B) in patients with recurrent epithelial ovarian cancer (rEOC).
Muggia, F.
Safra, T.
Borgato, L.
Gandhi, A.
Mancinc, G.
Gabizon, A.
Liebes, L.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

← 1 2 3 4 5 →